论文部分内容阅读
小细胞未分化肺癌(SCLC)的化、放综合治疗是目前最多采用,且疗效相对较好的治疗方案、但并发症,特别是造血系统的副反应较多。考虑到既要保证疗效的巩固,又能最大限度地避免不良反应的严重出现,我们采用化、放同时治疗模式并在后期巩固化疗中,以屎多胺等生化监测手段实施“有的放矢”的化疗,以避免盲目过多地用药。14例经监测化疗患者1、2年生存率分别为71.4％(10/14),28.6％(4/14),中位生存期为17个月,近期疗效尚满意。
The comprehensive treatment of small cell undifferentiated lung cancer (SCLC) is currently the most widely used treatment strategy with relatively good curative effect, but complications, especially the hematopoietic system have many side effects. Taking into account the need to ensure the consolidation of efficacy and to minimize the occurrence of adverse reactions to the maximum extent, we adopted a combination of chemotherapy and radiotherapy, and in the later period of consolidation chemotherapy, biochemical monitoring methods such as polyamines were used to implement “targeted” chemotherapy. To avoid blindly overdosing. The 1-year and 2-year survival rates of 14 patients with monitored chemotherapy were 71.4% (10/14) and 28.6% (4/14) respectively, and the median survival time was 17 months. The short-term efficacy was still satisfactory.